Why the study?
Do new oral anticoagulants reduce thromboembolic stroke, systemic embolism, and hemorrhagic stroke compared to warfarin and each other in patients with atrial fibrillation?
Do new oral anticoagulants reduce thromboembolic stroke, systemic embolism, and hemorrhagic stroke compared to warfarin and each other in patients with atrial fibrillation?
New oral anticoagulants offer superior safety over warfarin primarily driven by a significant reduction in hemorrhagic stroke, with dabigatran 150 mg twice daily showing the most favorable risk/benefit profile.
No takes yet. Share an insight, caveat, or question.
Supports preferring NOACs over warfarin in AF to reduce hemorrhagic stroke and mortality; reinforces Level 1 meta-analytic evidence for first-line use.
Testa et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: